AIxBio White Paper 4: Policy Options for AIxBio

To enable the convergence of artificial intelligence (AI) and biotechnology (AIxBio), policymakers could consider mechanisms that promote innovation while encouraging responsible development and continually assessing future risk. AI models are already transforming the way we use biology to produce pharmaceuticals, food, energy, and chemicals. The rapid advancement of AI used for biotechnology indicates that a breakthrough moment is likely in the near future. Companies in the United States, China, and elsewhere are actively pursuing such a “ChatGPT moment” for biological design tools. The United States must lead in the invention and application of such technologies so that we may realize the enormous benefit of AIxBio and lead in developing international norms for responsible innovation. This white paper lays out policy options to promote U.S. innovation, provide oversight of AI models for biotechnology, and assess future risk.    

Read the rest of the papers in this series here.